Biomarker Discovery Outsourcing Services Market Reach USD 52.82 Billion by 2031 with a CAGR of 20.15% | InsightAce Study States
November 30, 2023 06:09 ET
|
InsightAce Analytic Pvt. LTd.
Jersey City, NJ, Nov. 30, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Biomarker Discovery Outsourcing Services Market...
RetinalGeniX Technologies Inc. Appoints Stephen Tannenbaum to the Company's Business Advisory Board
November 28, 2023 16:01 ET
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. APPOINTS STEPHEN TANNENBAUM
TO THE COMPANY'S BUSINESS ADVISORY BOARD. RetinalGeniX is an ophthalmic R&D company
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
November 13, 2023 16:05 ET
|
Cyclacel
- Cyclacel Expects to Release Updated Phase 1/2 Clinical and Biomarker Data with Oral Fadraciclib and Provide Safety, Efficacy and Putative Mechanism Update for Oral Plogosertib - - Management to...
RetinalGeniX IRB Approved to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
October 30, 2023 14:51 ET
|
RetinalGeniX Technologies, Inc.
Proposed patient selection process is intended to reduce the cost and improve the safety and efficacy of patient candidate selection for ocular injections
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
October 26, 2023 09:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, today reports novel findings for its lead product, pepinemab, in a...
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
October 17, 2023 07:00 ET
|
AC Immune SA
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference Lausanne, Switzerland, October 17, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...
Allarity Therapeutics to Present at Biomarkers Europe 2023
October 02, 2023 07:00 ET
|
Allarity Therapeutics, Inc.
Allarity will present on development of several drug-specific DRP® companion diagnostics, and participate in a panel discussion with speakers from Merck and Roche BOSTON, October 2, 2023 —...
PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
August 30, 2023 16:05 ET
|
Allarity Therapeutics, Inc.
- The DRP®-Dovitinib companion diagnostic demonstrated an ability to identify advanced renal cell carcinoma patients that have improved clinical benefit from dovitinib treatment, as compared to...
Cancer Biomarker Market Size to Hit USD 27.8 Billion by 2030 at 9.8% CAGR – Report by Market Research Future (MRFR)
June 15, 2023 05:25 ET
|
Market Research Future
New York, USA, June 15, 2023 (GLOBE NEWSWIRE) -- Cancer Biomarker Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Cancer Biomarker Market Information...
Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study
March 16, 2023 07:00 ET
|
Purple Biotech Ltd.
Reduction in neutrophil extracellular traps (NETs) markersPotential association between patient survival and CEACAM1 positive lymphocytes REHOVOT, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- ...